Personalis, Inc. (NASDAQ:PSNL – Get Free Report) CFO Aaron Tachibana sold 40,000 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $12.01, for a total value of $480,400.00. Following the transaction, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at $2,387,984.33. This represents a 16.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Aaron Tachibana also recently made the following trade(s):
- On Friday, May 29th, Aaron Tachibana sold 38,799 shares of Personalis stock. The shares were sold at an average price of $11.58, for a total value of $449,292.42.
Personalis Trading Down 11.2%
Shares of Personalis stock opened at $10.75 on Friday. The firm has a market capitalization of $1.13 billion, a P/E ratio of -10.54 and a beta of 2.28. The business has a fifty day simple moving average of $7.23 and a two-hundred day simple moving average of $8.21. Personalis, Inc. has a 12 month low of $3.84 and a 12 month high of $12.53.
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on PSNL. BTIG Research lowered their price target on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Wall Street Zen raised Personalis from a “sell” rating to a “hold” rating in a research report on Saturday, May 30th. Morgan Stanley lowered their price target on Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Finally, Needham & Company LLC boosted their target price on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Personalis currently has a consensus rating of “Moderate Buy” and an average price target of $11.00.
View Our Latest Analysis on PSNL
Institutional Investors Weigh In On Personalis
Large investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd grew its stake in shares of Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after purchasing an additional 1,479 shares during the period. Legal & General Group Plc bought a new position in shares of Personalis during the 2nd quarter valued at approximately $30,000. International Assets Investment Management LLC bought a new position in shares of Personalis during the 4th quarter valued at approximately $31,000. BNP Paribas Financial Markets grew its stake in shares of Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after acquiring an additional 5,177 shares during the period. Finally, Focus Partners Wealth bought a new position in shares of Personalis during the 1st quarter valued at approximately $47,000. 61.91% of the stock is currently owned by institutional investors.
About Personalis
Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.
In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.
Featured Stories
- Five stocks we like better than Personalis
- Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.
